VANCOUVER, British Columbia--(BUSINESS WIRE)--May 24, 2006--Data from two early-stage clinical trials presented today at the World Federation of Hemophilia (WFH) conference offer promising results and support further development for a new experimental factor VIII replacement product, BAY 79-4980. The findings suggest that this new product may offer people with hemophilia A (factor VIII deficiency) prolonged protection from bleeding with once-weekly infusions.
